Johnson & Johnson JNJ Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Sales to customers (Note 9) by Business | ||||||
| Innovative Medicine | $15.43B-2.1% | $15.76B+1.3% | $15.56B+2.4% | $15.2B+9.6% | $13.87B-3.2% | |
| MEDTECH | $8.64B-1.9% | $8.8B+4.4% | $8.43B-1.3% | $8.54B+6.5% | $8.02B-2.1% | |
| Sales to customers (Note 9) by Product | ||||||
| ADVANCED | $1.12B-4.4% | $1.18B+0.9% | $1.17B+0.1% | $1.16B+8.5% | $1.07B-6.8% | |
| CAPLYTA | $270M+8.4% | $249M+3.8% | $240M+13.7% | $211M— | $0— | |
| CARVYKTI | $597M+7.6% | $555M+5.9% | $524M+19.4% | $439M+19.0% | $369M+10.5% | |
| CONCERTA/Methylphenidate | $136M+3.0% | $132M-5.7% | $140M-14.6% | $164M+10.8% | $148M-6.9% | |
| CONTACT LENSES / OTHER | $969M-3.9% | $1.01B-1.0% | $1.02B+5.5% | $965M+5.0% | $919M-1.9% | |
| DARZALEX | $3.96B+1.6% | $3.9B+6.3% | $3.67B+3.8% | $3.54B+9.3% | $3.24B+5.0% | |
| EDURANT/rilpivirine | $409M+6.8% | $383M-0.5% | $385M+6.9% | $360M+0.6% | $358M+11.2% | |
| ERLEADA | $949M-1.0% | $959M+2.5% | $936M+3.1% | $908M+17.8% | $771M-1.7% | |
| GENERAL | $1.39B-5.4% | $1.47B+6.5% | $1.38B-0.9% | $1.39B+5.1% | $1.32B-2.5% | |
| HIPS | $436M-0.7% | $439M+8.4% | $405M-3.8% | $421M+2.9% | $409M-2.2% | |
| IMBRUVICA | $660M-3.5% | $684M-1.6% | $695M-5.4% | $735M+3.7% | $709M-3.0% | |
| INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA | $1.04B+5.3% | $986M+6.1% | $929M-6.4% | $992M+9.9% | $903M-15.1% | |
| KNEES | $420M-2.8% | $432M+14.6% | $377M-3.1% | $389M0.0% | $389M-2.3% | |
| OPSUMIT/OPSYNVI | $606M— | —— | $578M-0.7% | $582M+11.5% | $522M— | |
| OTHER IMMUNOLOGY | $46M+15.0% | $40M+233% | $12M+50.0% | $8M+700% | $1M— | |
| OTHER INFECTIOUS DISEASES | $37M-7.5% | $40M-14.9% | $47M0.0% | $47M+14.6% | $41M-8.9% | |
| OTHER NEUROSCIENCE | $262M+6.9% | $245M-4.3% | $256M-5.2% | $270M-2.5% | $277M+8.6% | |
| Other Oncology | $192M+92.0% | $100M+6.4% | $94M+1.1% | $93M-56.5% | $214M+185% | |
| Other | $2.9B+1,064% | $249M-5.7% | $264M-14.6% | $309M-89.1% | $2.84B+911% | |
| PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA | $443M+15.7% | $383M-3.5% | $397M+0.3% | $396M-1.7% | $403M-1.0% | |
| Remicade | $422M+14.1% | $370M-22.3% | $476M+4.6% | $455M-2.6% | $467M+30.1% | |
| RYBREVANT + LAZCLUZE | $257M+19.0% | $216M+9.1% | $198M+10.6% | $179M+27.0% | $141M+15.6% | |
| SIMPONI / SIMPONI ARIA | $647M+2.4% | $632M-8.0% | $687M-0.4% | $690M+4.7% | $659M+13.0% | |
| SPINE & OTHER | $694M— | —— | $698M-4.0% | $727M+8.3% | $671M— | |
| SPRAVATO | $468M-7.0% | $503M+9.6% | $459M+10.9% | $414M+29.4% | $320M+7.7% | |
| STELARA | $656M-46.7% | $1.23B-21.7% | $1.57B-5.0% | $1.65B+1.7% | $1.63B-30.8% | |
| SURGICAL | $396M-3.6% | $411M+7.3% | $383M-5.0% | $403M+11.6% | $361M-1.1% | |
| TALVEY | $152M+2.0% | $149M+22.1% | $122M+15.1% | $106M+23.3% | $86M+1.2% | |
| Tecvayli | $202M+14.8% | $176M-0.6% | $177M+6.6% | $166M+9.9% | $151M+3.4% | |
| TRAUMA | $833M+2.5% | $813M+2.5% | $793M+3.3% | $768M-0.5% | $772M+1.0% | |
| Tremfya | $1.61B+1.2% | $1.59B+11.6% | $1.42B+20.1% | $1.19B+24.1% | $956M+0.7% | |
| UPTRAVI | $483M-1.6% | $491M+1.4% | $484M+1.7% | $476M+5.5% | $451M-3.0% | |
| XARELTO | $642M-6.6% | $687M+8.2% | $635M+2.3% | $621M-10.0% | $690M+2.1% | |
| Sales to customers (Note 9) by Geography | ||||||
| Asia-Pacific, Africa | $3.59B+2.6% | $3.5B-3.2% | $3.61B+0.2% | $3.61B+8.9% | $3.31B+1.6% | |
| Europe | $5.85B+4.5% | $5.6B+2.9% | $5.44B+1.0% | $5.39B+5.4% | $5.11B+3.8% | |
| United States | $13.33B-6.1% | $14.2B+3.6% | $13.71B+1.2% | $13.54B+10.1% | $12.31B-6.8% | |
| Western Hemisphere, excluding U.S. | $1.29B+1.7% | $1.27B+3.2% | $1.23B+2.1% | $1.21B+3.3% | $1.17B+2.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Johnson & Johnson break its business down?
- Johnson & Johnson (JNJ) reports sales to customers (note 9) by business across 2 parts — Innovative Medicine and MEDTECH. Each is extracted from the segment footnotes and tracked over time.
- Where does Johnson & Johnson's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Johnson & Johnson's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
